ENDONOVO THERAPEUTICS, INC. (ENDV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 60K 120K 180K Q4 '18: 42.1K Q1 '19: 45K Q2 '19: 62.7K Q3 '19: 54K Q4 '19: 148.4K Q1 '20: 69.7K Q2 '20: 44.6K Q3 '20: 40K Q4 '20: 11.5K Q1 '21: 34.7K Q2 '21: 30.3K Q3 '21: 7.8K Q4 '21: 316 Q1 '22: 2.3K Q2 '22: 650 Q3 '22: 11K Q4 '22: 121.5K Q1 '23: 87.5K Q2 '23: 45.2K Q3 '23: 1.5K Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Gross Profit Quarterly

0 40K 80K 120K Q2 '18: 12.3K Q3 '18: 17K Q4 '18: 34.1K Q1 '19: 37.2K Q2 '19: 33.2K Q3 '19: 45.1K Q4 '19: 101.3K Q1 '20: 63.4K Q2 '20: 33.3K Q3 '20: 39.2K Q1 '21: 32.2K Q2 '21: 29.8K Q3 '21: 4.7K Q1 '22: 1.6K Q2 '22: 267 Q3 '22: 6.9K Q4 '22: 116.6K Q1 '23: 83.5K Q2 '23: 45.2K Q3 '23: 693 Q3 '18 Q2 '19 Q1 '20 Q1 '21 Q1 '22 Q4 '22 Q3 '23

Operating Income Quarterly

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q4 '18: -1M Q1 '19: -813K Q2 '19: -974.8K Q3 '19: -1.3M Q4 '19: -730K Q1 '20: -679.6K Q2 '20: -601.8K Q3 '20: -946.8K Q4 '20: -684K Q1 '21: -590.4K Q2 '21: -570.1K Q3 '21: -692.3K Q4 '21: -373.8K Q1 '22: -485.8K Q2 '22: -1.8M Q3 '22: -496.8K Q4 '22: -483.1K Q1 '23: -529.3K Q2 '23: -1.1M Q3 '23: -472.8K Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q4 '18: 1.4M Q1 '19: -2.4M Q2 '19: -7.8M Q3 '19: -1.4M Q4 '19: -5.7M Q1 '20: 4.3M Q2 '20: -1.6M Q3 '20: -1.1M Q4 '20: -2M Q1 '21: -2.7M Q2 '21: -1.3M Q3 '21: -1.5M Q4 '21: 2.4M Q1 '22: -2.4M Q2 '22: -2.5M Q3 '22: -603.4K Q4 '22: -12.9M Q1 '23: 7.2M Q2 '23: 2.1M Q3 '23: -766.2K Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Cost of Revenue Quarterly

0 20K 40K 60K Q4 '18: 8.1K Q1 '19: 7.7K Q2 '19: 29.6K Q3 '19: 8.9K Q4 '19: 47.2K Q1 '20: 6.3K Q2 '20: 11.3K Q3 '20: 760 Q4 '20: 47K Q1 '21: 2.5K Q2 '21: 500 Q3 '21: 3.1K Q4 '21: 8.9K Q1 '22: 714 Q2 '22: 383 Q3 '22: 4K Q4 '22: 4.9K Q1 '23: 4K Q2 '23: 0 Q3 '23: 827 Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Operating Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q4 '18: -716.1K Q1 '19: -528.2K Q2 '19: -687.6K Q3 '19: -1M Q4 '19: -308.4K Q1 '20: -297.2K Q2 '20: -154.8K Q3 '20: -96.7K Q4 '20: -192.9K Q1 '21: -289.9K Q2 '21: -135.9K Q3 '21: -169.4K Q4 '21: -391.3K Q1 '22: -123K Q2 '22: -206.5K Q3 '22: -123.9K Q4 '22: -225.5K Q1 '23: -173.2K Q2 '23: -165.8K Q3 '23: -65.4K Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23

Free Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q1 '18: -599.7K Q2 '18: -741.6K Q3 '18: -830.4K Q4 '18: -716.1K Q3 '19: -1M Q4 '19: -308.4K Q1 '18 Q2 '18 Q3 '18 Q4 '18 Q3 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q2 '13: 68.7M Q3 '13: 73.1M Q2 '16: 111.8M Q2 '17: 330.8M Q2 '18: 347.9M Q1 '19: 481.8K Q2 '19: 577.5K Q3 '19: 777.2K Q1 '20: 11.9M Q2 '20: 9.8M Q3 '20: 16.1M Q1 '21: 41.6M Q2 '21: 58.5M Q3 '21: 66.3M Q1 '22: 79M Q2 '22: 134.4M Q3 '22: 153.6M Q1 '23: 1.7B Q2 '23: 1.4B Q3 '23: 1.4B Q3 '13 Q2 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q2 '18: 0.00 Q3 '18: 0.01 Q4 '18: -17.76 Q1 '19: -22.75 Q2 '19: -36.32 Q3 '19: -38.11 Q4 '19: -45.18 Q1 '20: -40.33 Q2 '20: -26.93 Q3 '20: -25.19 Q4 '20: -0.03 Q1 '21: 0.05 Q2 '21: 0.20 Q3 '21: 0.25 Q4 '21: -0.05 Q1 '22: -0.02 Q2 '22: -0.02 Q3 '22: 0.00 Q4 '22: -0.13 Q1 '23: -0.10 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.